Pipeline and BC007 Mode of Action
Our candidate BC007 is a non-modified DNA aptamer out of a family of aptamers that bind to and lead to the neutralization of autoantibodies that are directed against G-protein-coupled receptors (GPCR-AABs). BC007 binds to ß1-adrenergic-receptor-autoantibodies.
BC 007 was successfully tested in a Phase-1 clinical trial. This study included a sub-group of subjects that are tested positive for GPCR-autoantibodies and which are otherwise healthy. The study design allowed for the proof that BC007 can neutralize GPCR-autoantibodies in humans.
The full study design is published on clinicaltrials.gov
Mode of Action
This video sequence demonstrates the mechanism of action of BC007